Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Incyte Corporation    INCY

Delayed Quote. Delayed  - 12/09 10:14:59 pm
100.63 USD   -2.19%
12/08 NASDAQ 100 MOVE : Incy, cost
12/07 NASDAQ 100 MOVE : Incy, wdc
12/04 INCYTE : Pooled Analysis of Five-Year Data from Two Phase 3 Studies ..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
Latest news on INCYTE CORPORATION
12/08 AGENUS : Announces Commencement of Phase 1/2 Clinical Trial of anti-OX40 Checkpo..
12/08 NASDAQ 100 MOVERS : Incy, cost
12/07 NASDAQ 100 MOVERS : Incy, wdc
12/04 INCYTE : Pooled Analysis of Five-Year Data from Two Phase 3 Studies Further Supp..
12/03 INCYTE : CURE Magazine Hosts 4th Annual Gala Honoring MPN Heroes
12/02 INCYTE : CURE® Magazine Hosts 4th Annual Gala Honoring MPN Heroes®
11/30 AGENUS INC. (NASDAQ : AGEN) Files An 8-K Other Events
11/14 INCYTE : New Analyses of Phase 3 Trials Show Improvements in Rheumatoid Arthriti..
11/14 INCYTE : Baricitinib Demonstrates Early Response Compared to Placebo and Signifi..
11/10 INCYTE : to Present at Upcoming Investor Conference
11/08 INCYTE : and GENESIS Pharma Announce a Commercialization Agreement for Iclusig® ..
11/03 INCYTE : More Than 20 Abstracts Highlighting Data from Incyte’s Portfolio ..
11/02 INCYTE : to Present at Upcoming Investor Conference
11/01 INCYTE : Management's Discussion and Analysis of Financial Condition and Results..
11/01 INCYTE CORP : Results of Operations and Financial Condition, Financial Statement..
11/01 INCYTE : Reports 2016 Third-Quarter Financial Results and Updates Key Clinical P..
11/01 INCYTE : posts solid earnings performance in third quarter
10/27 AGENUS INC. (NASDAQ : AGEN) Files An 8-K Reports Third Quarter Financial Results..
10/27INCYTE CORPORATION : quaterly earnings release
10/17 NASDAQ 100 MOVERS : Incy, mat
10/14 INCYTE : to Report Third Quarter Financial Results
10/07 NASDAQ 100 MOVERS : Lbtyk, incy
10/07 INCYTE : CURE Magazine to Host Recognition Gala for Heroes in Rare Blood Cancer ..
10/07 INCYTE : Additional Phase 1 Data from ECHO-202 Reinforce Durability of Response ..
10/06 NASDAQ 100 MOVERS : Tsla, lrcx
09/28 NASDAQ 100 MOVERS : Payx, incy
09/28 INCYTE : Updated Phase 1 Data Reinforce the Clinical Profile of Epacadostat in C..
09/27 INCYTE : NCCN Guidelines® Recommend Jakafi® (ruxolitinib) for the Treatment of M..
09/26 NASDAQ 100 MOVERS : Ntes, wdc
09/15 NASDAQ 100 MOVERS : Incy, swks
09/08 INCYTE : Supports Those Affected by Rare Blood Cancers on MPN Awareness Day and ..
09/01 INCYTE : Forbes Magazine Names Incyte to its List of World's Most Innovative Com..
08/30 INCYTE : to Present at Upcoming Investor Conferences
08/29 INCYTE : Immunovaccine Announces Additional Positive Topline Results from Phase ..
08/29 INCYTE : ranks 4th on Forbes list of Innovative companies
08/25 INCYTE : Forbes Magazine Names Incyte to its List of World’s Most Innovati..
08/24 NASDAQ 100 MOVERS : Intu, incy
08/23 NASDAQ 100 MOVERS : Myl, amat
08/22 NASDAQ 100 MOVERS : Viab, incy
08/12 MADRIGAL PHARMACEUTICALS : Richard S. Levy, M. D., Appointed to Madrigal Board o..
08/11 NASDAQ 100 MOVERS : Incy, yhoo
08/09 INCYTE : Management's Discussion and Analysis of Financial Condition and Results..
08/09 INCYTE : beats Street 2Q forecasts
08/09 INCYTE CORP : Results of Operations and Financial Condition, Financial Statement..
08/09 INCYTE : Reports 2016 Second-Quarter Financial Results and Updates Key Clinical ..
08/09 INCYTE : earnings, sales soar
08/08 NASDAQ 100 MOVERS : Nflx, qvca
08/04INCYTE CORPORATION : half-yearly earnings release
07/19 INCYTE CORP : Change in Directors or Principal Officers (form 8-K)
07/19 INCYTE : Updated Data for Epacadostat, Incyte’s Selective IDO1 Inhibitor, ..
07/15 NASDAQ 100 MOVERS : Nclh, incy
07/14 NASDAQ 100 MOVERS : Nxpi, csx
07/14 INCYTE : to Report Second Quarter Financial Results
07/06 NASDAQ 100 MOVERS : Aal, endp
07/01 INCYTE : Financial Statements and Exhibits (form 8-K/A)
06/30 INCYTE : FDA Grants Breakthrough Therapy Designation for Incyte's Ruxolitinib Ja..
06/30 INCYTE : Announces First Patient Treated in ECHO-301 Phase 3 Study
06/23 INCYTE : FDA Grants Breakthrough Therapy Designation for Incyte’s Ruxoliti..
06/22 INCYTE : Announces First Patient Treated in ECHO-301 Phase 3 Study
06/22 INCYTE : Phase I/II trial of INCAGN1876 in solid tumours starts
06/16 ELI LILLY : Baricitinib significantly reduces joint damage progression in rheuma..
06/11 INCYTE : study shows good response to treatment for some PV blood cancer patient..
06/10 INCYTE : New Phase 3 Data Show Jakafi® (ruxolitinib) is Superior to Best Availab..
06/09 INCYTE : and Moffitt Cancer Center Establish Multi-Year Oncology Research Allian..
06/09 INCYTE : Announces the Launch of the Incyte Charitable Giving Foundation
06/09 INCYTE : Baricitinib significantly reduces joint damage progression in rheumatoi..
06/09 INCYTE : Patient-reported outcomes across phase 3 studies of baricitinib demonst..
06/06 NASDAQ 100 MOVERS : Fast, wfm
06/06 INCYTE : Five-year Results from Phase 3 Study of Jakafi® (ruxolitinib) Show Sust..
06/02 INCYTE : forms charitable foundation to meet needs in Delaware
06/01 INCYTE CORP : Entry into a Material Definitive Agreement, Completion of Acquisit..
06/01 INCYTE : and Moffitt team up for blood cancer research programmes
06/01 INCYTE : and Moffitt Cancer Center Establish Multi-Year Oncology Research Allian..
05/31 INCYTE : Announces the Launch of the Incyte Charitable Giving Foundation
05/27 INCYTE CORP : Change in Directors or Principal Officers, Submission of Matters t..
1  2  3  4  5  6Next
Advertisement
Financials ($)
Sales 2016 1 102 M
EBIT 2016 116 M
Net income 2016 116 M
Finance 2016 55,2 M
Yield 2016 -
P/E ratio 2016 176,14
P/E ratio 2017 64,47
EV / Sales 2016 17,2x
EV / Sales 2017 12,2x
Capitalization 18 957 M
More Financials
Chart INCYTE CORPORATION
Duration : Period :
Incyte Corporation Technical Analysis Chart | INCY | US45337C1027 | 4-Traders
Full-screen chart
Technical analysis trends INCYTE CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 109 $
Spread / Average Target 8,5%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Hervé Hoppenot Chairman, President & Chief Executive Officer
David W. Gryska Chief Financial Officer & Executive Vice President
Reid M. Huber Chief Scientific Officer & Executive VP
Steven H. Stein Chief Medical Officer & Senior Vice President
Paul Alan Brooke Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
INCYTE CORPORATION-7.21%18 957
QUINTILES IMS HOLDINGS..14.10%19 286
CELLTRION, INC.--.--%9 997
LONZA GROUP AG9.20%9 261
SEATTLE GENETICS, INC.44.54%9 183
ALKERMES PLC-30.12%8 430
More Results